Analyst Ratings for PDL BioPharma (PDLI)
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
N/A
Rating Score: 3.3 / 10
Percentile Rank: 30%
Rating Score: 3.3 / 10
Percentile Rank: 30%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/22/2016 | Piper Sandler | N/A | New Coverage | Overweight (N/A) |
4.00 (N/A) |
2.08 (2.47) |
18.75% | Details |
| 1/15/2013 | Credit Suisse | N/A | Downgrade | Underperform (Neutral) |
N/A (N/A) |
7.42 (2.47) |
-66.71% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
